CSat Investment Advisory’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
$5K Sell
25
-1
-4% -$196 ﹤0.01% 493
2020
Q4
$4K Sell
26
-4,981
-99% -$744K ﹤0.01% 492
2020
Q3
$741K Buy
5,007
+509
+11% +$78.8K 0.07% 137
2020
Q2
$739K Sell
4,498
-281
-6% -$43.1K 0.09% 119
2020
Q1
$663K Buy
4,779
+1,264
+36% +$174K 0.14% 97
2019
Q4
$462K Buy
3,515
+1,447
+70% +$168K 0.12% 156
2019
Q3
$231K Buy
2,068
+246
+14% +$27.4K 0.07% 191
2019
Q2
$202K Buy
1,822
+1,801
+8,576% +$212K 0.07% 186
2019
Q1
$3K Hold
21
﹤0.01% 529
2018
Q4
$2K Buy
21
+2
+11% +$223 ﹤0.01% 530
2018
Q3
$2K Sell
19
-5
-21% -$500 ﹤0.01% 527
2018
Q2
$2K Buy
+24
New +$1.97K ﹤0.01% 528

Other funds holding LLY

CSat Investment Advisory's LLY Position: Q1 2021 in Review

CSat Investment Advisory reduced its Eli Lilly (LLY) stake by 3.8% in Q1 2021, selling an estimated $196 and leaving 25 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #493.

CSat Investment Advisory first reported a position in LLY in Q2 2018 and has held it in 12 quarters since. The position peaked at $741K in Q3 2020. 1,949 funds tracked by Wall St. Rank hold LLY as of Q1 2021.

  • CSat Investment Advisory held 25 shares of Eli Lilly worth $5K as of Q1 2021.
  • CSat Investment Advisory sold 1 Eli Lilly share in Q1 2021, an estimated $196.
  • Eli Lilly made up ﹤0.01% of CSat Investment Advisory's portfolio in Q1 2021, its #493 holding.
  • CSat Investment Advisory first reported a position in Eli Lilly in Q2 2018 and has held it in 12 quarters since.
  • CSat Investment Advisory's Eli Lilly position peaked at $741K in Q3 2020.
  • 1,949 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2021.

Based on CSat Investment Advisory's 13F filing for Q1 2021, filed 13 May 2021.